title: [The pharmacokinetic and pharmacodynamic characteristics of foridon during interaction with the metabolic oxidation inhibitor dopegit].
abstract: The paper deals with some aspects of the effects produced by dopegite on the pharmacokinetics and pharmacodynamics of foridone from a group of calcium antagonists. Nineteen patients with essential hypertension received a single doses of foridone of 40 mg, then its course therapy in a dose of 90 mg/day for 2 weeks, then it was supplemented with dopegite in a dose of 750 mg/day for 2 weeks too. Supplementation of dopegite caused statistically significant changes as higher plasma concentrations of foridone and increased concentration-time curve areas, decreased total peripheral resistance and regional, and a lower spasm index. Dopegite can be used to enhance the antihypertensive effect of foridone.
authors.forename: V G
authors.initials: VG
authors.lastname: Kukes
authors.forename: S N
authors.initials: SN
authors.lastname: Alekhin
authors.forename: A S
authors.initials: AS
authors.lastname: Rumiantsev
authors.forename: E T
authors.initials: ET
authors.lastname: Gneushev
authors.forename: A S
authors.initials: AS
authors.lastname: Gushchin
authors.forename: D V
authors.initials: DV
authors.lastname: Germanov
mesh_terms: D000328:Adult; D002121:Calcium Channel Blockers / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008750:Methyldopa / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use; D008875:Middle Aged; D009543:Nifedipine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D010084:Oxidation-Reduction / Q000187:drug effects; D013997:Time Factors
chemical_list: D002121:Calcium Channel Blockers; D008750:Methyldopa; D009543:Nifedipine; C045912:ryodipine
vernacular_title: Osobennosti farmakokinetiki i farmakodinamiki foridona pri vzaimodeĭstvii s ingibitorom metabolicheskogo okisleniia dopegitom.